Delving Into Participation Trends of Scleroderma Clinical Trials

NCT06264492 | Not Yet Recruiting

• 1 other identifier: 55777205
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Typically, specific demographic subsets tend to exhibit greater engagement in medical research. Nonetheless, there is insufficient research elucidating the trial characteristics influencing the participation of these particular demographics. The study will analyze data from diverse demographic viewpoints to uncover recurring trends that could provide valuable insights for future patients with scleroderma.

Conditions

Scleroderma

Keywords

scleroderma

Outcome Measures

Primary Outcomes (2)

• Rate of patients in clinical research for scleroderma

  3 months

• Number of scleroderma study participants who stay committed until clinical study wraps up

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients diagnosed with scleroderma who are actively considering participation in a clinical trial for this ailment, but have not yet concluded the enrollment and randomization phases.

You may qualify if:

• Patient has been diagnosed with scleroderma
• Patient has self-identified as planning to enroll in an observational clinical trial
• Patient is a minimum of 18 years or older

You may not qualify if:

• Patient is pregnant
• Inability to perform regular electronic reporting
• Patient does not understand, sign, and return consent form

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Study Sites (1)

Power Life Sciences

San Francisco, California, 94107, United States

Location

Related Publications (3)

• Careta MF, Leite Cda C, Cresta F, Albino J, Tsunami M, Romiti R. Prospective study to evaluate the clinical and radiological outcome of patients with scleroderma of the face. Autoimmun Rev. 2013 Sep;12(11):1064-9. doi: 10.1016/j.autrev.2013.05.005. Epub 2013 Jun 19.

  PMID: 23791631 BACKGROUND

• Harb S, Pelaez S, Carrier ME, Kwakkenbos L, Bartlett SJ, Hudson M, Mouthon L, Sauve M, Welling J, Shrier I, Thombs BD; SPIN Physical Activity Enhancement Patient Advisory Team and SPIN Investigators. Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care Res (Hoboken). 2022 Aug;74(8):1300-1310. doi: 10.1002/acr.24567. Epub 2022 May 11.

  PMID: 33527717 BACKGROUND

• Li SC. Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments. Curr Opin Rheumatol. 2022 Sep 1;34(5):245-254. doi: 10.1097/BOR.0000000000000886.

  PMID: 35880663 BACKGROUND

MeSH Terms

Conditions

Scleroderma, Diffuse

Condition Hierarchy (Ancestors)

Scleroderma, Systemic; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

4159004227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2024
• First Posted: February 20, 2024
• Study Start: March 1, 2025
• Primary Completion: March 1, 2026
• Study Completion (Estimated): March 1, 2027
• Last Updated: February 28, 2024

Record last verified: 2024-02

Locations

US (1)